Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States.

Wilkinson L, Hunt B, Johansen P, Iyer NN, Dang-Tan T, Pollock RF

Diabetes therapy : research, treatment and education of diabetes and related disorders19 Mar 2018Cited by 18 (Europe PMC)

PMID29557057PMCIDPMC5984908DOI10.1007/s13300-018-0402-8PepBankPUB-29557057

Read at source PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01Computer modelNot a test of Semaglutide aloneIn silicoOther
In a T2D cost analysis, more patients reached HbA1c targets with semaglutide than dulaglutide.
In plain wordsIn a T2D cost analysis, HbA1c target attainment was higher with semaglutide than dulaglutide.
Peptide
Semaglutide
Outcome
IncreaseHbA1c target attainment
Study
n: not reported in source
Comparator
Dulaglutide
Outcome group
Glycemic control · Whole body
Source sentences
Summary
More patients reached HbA1c targets with once-weekly semaglutide than with dulaglutide, and once-weekly semaglutide showed lower costs of control for all modeled endpoints.
1 context sentence(design, population, supporting numbers)
Summary · context
Numbers needed to treat and annual cost per patient achieving HbA1c targets (including a triple composite endpoint of HbA1c < 7% without hypoglycemia and no weight gain) or weight loss responses were calculated on the basis of data from SUSTAIN 7 and the annual cost of treatment from a US healthcare payer perspective.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2955705701
02Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a T2D cost analysis, fewer patients reached HbA1c targets with dulaglutide than semaglutide.
In plain wordsIn a T2D cost analysis, HbA1c target attainment was lower with dulaglutide than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c target attainment
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Glycemic control · Whole body
Source sentences
Summary
More patients reached HbA1c targets with once-weekly semaglutide than with dulaglutide, and once-weekly semaglutide showed lower costs of control for all modeled endpoints.
1 context sentence(design, population, supporting numbers)
Summary · context
Numbers needed to treat and annual cost per patient achieving HbA1c targets (including a triple composite endpoint of HbA1c < 7% without hypoglycemia and no weight gain) or weight loss responses were calculated on the basis of data from SUSTAIN 7 and the annual cost of treatment from a US healthcare payer perspective.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2955705702
03Computer modelNot a test of Semaglutide aloneIn silicoOther
In a T2D model, semaglutide had lower costs of control than dulaglutide across all modeled endpoints.
In plain wordsIn a T2D model, semaglutide had lower costs of control than dulaglutide across all modeled endpoints.
Peptide
Semaglutide
Outcome
DecreaseCost of control across modeled endpoints
Study
n: not reported in source
Comparator
Dulaglutide
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
More patients reached HbA1c targets with once-weekly semaglutide than with dulaglutide, and once-weekly semaglutide showed lower costs of control for all modeled endpoints.
1 context sentence(design, population, supporting numbers)
Summary · context
Numbers needed to treat and annual cost per patient achieving HbA1c targets (including a triple composite endpoint of HbA1c < 7% without hypoglycemia and no weight gain) or weight loss responses were calculated on the basis of data from SUSTAIN 7 and the annual cost of treatment from a US healthcare payer perspective.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2955705703
04Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a T2D model, dulaglutide had higher costs of control than semaglutide across all modeled endpoints.
In plain wordsIn a T2D model, dulaglutide had higher costs of control than semaglutide across all modeled endpoints.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCost of control across modeled endpoints
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
More patients reached HbA1c targets with once-weekly semaglutide than with dulaglutide, and once-weekly semaglutide showed lower costs of control for all modeled endpoints.
1 context sentence(design, population, supporting numbers)
Summary · context
Numbers needed to treat and annual cost per patient achieving HbA1c targets (including a triple composite endpoint of HbA1c < 7% without hypoglycemia and no weight gain) or weight loss responses were calculated on the basis of data from SUSTAIN 7 and the annual cost of treatment from a US healthcare payer perspective.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2955705704
05Computer modelNot a test of Semaglutide aloneIn silicoOther
In a T2D model, semaglutide had lower costs per triple-composite responder than dulaglutide at the higher compared doses.
In plain wordsIn a T2D model, semaglutide had lower costs per triple-composite responder than dulaglutide at the higher compared doses.
Peptide
Semaglutide
Outcome
DecreaseCost per triple-composite responder, higher doses
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Outcome group
Cost-effectiveness · Whole body
Measurements
Cost per responder
11,916 USD
semaglutide 1.0 mg
Cost per responder
15,204 USD
dulaglutide 1.5 mg
Source sentences
Summary
The cost per patient achieving the triple composite endpoint was USD 11,916 with once-weekly semaglutide 1.0 mg and USD 15,204 with dulaglutide 1.5 mg, representing a 28% larger cost with dulaglutide 1.5 mg.
1 context sentence(design, population, supporting numbers)
Summary · context
Numbers needed to treat and annual cost per patient achieving HbA1c targets (including a triple composite endpoint of HbA1c < 7% without hypoglycemia and no weight gain) or weight loss responses were calculated on the basis of data from SUSTAIN 7 and the annual cost of treatment from a US healthcare payer perspective.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2955705705
06Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a T2D model, dulaglutide had a 28% higher cost per triple-composite responder than semaglutide at the higher compared doses.
In plain wordsIn a T2D model, dulaglutide had a 28% higher cost per triple-composite responder than semaglutide at the higher compared doses.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCost per triple-composite responder, higher doses
Study
n: not reported in source
Comparator
Semaglutide 1.0 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
The cost per patient achieving the triple composite endpoint was USD 11,916 with once-weekly semaglutide 1.0 mg and USD 15,204 with dulaglutide 1.5 mg, representing a 28% larger cost with dulaglutide 1.5 mg.
1 context sentence(design, population, supporting numbers)
Summary · context
Numbers needed to treat and annual cost per patient achieving HbA1c targets (including a triple composite endpoint of HbA1c < 7% without hypoglycemia and no weight gain) or weight loss responses were calculated on the basis of data from SUSTAIN 7 and the annual cost of treatment from a US healthcare payer perspective.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2955705706
07Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a T2D model, dulaglutide had a 68% higher cost per triple-composite responder than semaglutide at the lower compared doses.
In plain wordsIn a T2D model, dulaglutide had a 68% higher cost per triple-composite responder than semaglutide at the lower compared doses.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCost per triple-composite responder, lower doses
Study
n: not reported in source
Comparator
Semaglutide 0.5 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
The cost of reaching the target was 68% larger with dulaglutide 0.75 mg versus once-weekly semaglutide 0.5 mg.
1 context sentence(design, population, supporting numbers)
Summary · context
Numbers needed to treat and annual cost per patient achieving HbA1c targets (including a triple composite endpoint of HbA1c < 7% without hypoglycemia and no weight gain) or weight loss responses were calculated on the basis of data from SUSTAIN 7 and the annual cost of treatment from a US healthcare payer perspective.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2955705707
08Computer modelNot a test of Semaglutide aloneIn silicoOther
In a T2D model, semaglutide had lower costs per triple-composite responder than dulaglutide at the lower compared doses.
In plain wordsIn a T2D model, semaglutide had lower costs per triple-composite responder than dulaglutide at the lower compared doses.
Peptide
Semaglutide
Outcome
DecreaseCost per triple-composite responder, lower doses
Study
n: not reported in source
Comparator
Dulaglutide 0.75 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
The cost of reaching the target was 68% larger with dulaglutide 0.75 mg versus once-weekly semaglutide 0.5 mg.
1 context sentence(design, population, supporting numbers)
Summary · context
Numbers needed to treat and annual cost per patient achieving HbA1c targets (including a triple composite endpoint of HbA1c < 7% without hypoglycemia and no weight gain) or weight loss responses were calculated on the basis of data from SUSTAIN 7 and the annual cost of treatment from a US healthcare payer perspective.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2955705708
09Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a T2D model, dulaglutide had an 18% higher cost per HbA1c target responder than semaglutide at the higher compared doses.
In plain wordsIn a T2D model, dulaglutide had an 18% higher cost per HbA1c target responder than semaglutide at the higher compared doses.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCost per HbA1c below 7% responder
Study
n: not reported in source
Comparator
Semaglutide 1.0 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
For each patient achieving an HbA1c < 7%, the cost would be 18% larger with dulaglutide 1.5 mg than with once-weekly semaglutide 1.0 mg.
1 context sentence(design, population, supporting numbers)
Summary · context
Numbers needed to treat and annual cost per patient achieving HbA1c targets (including a triple composite endpoint of HbA1c < 7% without hypoglycemia and no weight gain) or weight loss responses were calculated on the basis of data from SUSTAIN 7 and the annual cost of treatment from a US healthcare payer perspective.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2955705709
10Computer modelNot a test of Semaglutide aloneIn silicoOther
In a T2D model, semaglutide had lower costs per HbA1c target responder than dulaglutide at the higher compared doses.
In plain wordsIn a T2D model, semaglutide had lower costs per HbA1c target responder than dulaglutide at the higher compared doses.
Peptide
Semaglutide
Outcome
DecreaseCost per HbA1c below 7% responder
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
For each patient achieving an HbA1c < 7%, the cost would be 18% larger with dulaglutide 1.5 mg than with once-weekly semaglutide 1.0 mg.
1 context sentence(design, population, supporting numbers)
Summary · context
Numbers needed to treat and annual cost per patient achieving HbA1c targets (including a triple composite endpoint of HbA1c < 7% without hypoglycemia and no weight gain) or weight loss responses were calculated on the basis of data from SUSTAIN 7 and the annual cost of treatment from a US healthcare payer perspective.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2955705710

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02648204

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

Novo Nordisk A/Sn = 1,2016 Jan 2016 to 19 May 2017

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 15 Oct 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC